Evidence map›Paper›PMID 34200156›Full record

ArticleCancers2021

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities.

Michala Skovlund Sørensen, Thomas Colding-Rasmussen, Peter Frederik Horstmann, Klaus Hindsø, Christian Dehlendorff, Julia Sidenius Johansen, Michael Mørk Petersen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michala Skovlund SørensenMusculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, Denmark.ORCID 0000-0003-0123-2666
Thomas Colding-RasmussenMusculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Peter Frederik HorstmannMusculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Klaus HindsøPediatric Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
Christian DehlendorffStatistics and Data Analysis Danish Cancer Society Research Center, 2100 Copenhagen Ø, Denmark.
Julia Sidenius JohansenDepartment of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark.
Michael Mørk PetersenMusculoskeletal Tumor Section, Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen, 2100 Copenhagen Ø, Denmark.
University of Copenhagen · DKDanish Cancer Society · DK

Funding

Board of management Rigshospitalet NoneBrøderne Hartmanns foundation noneCapital Region of Denmark Research and Innovation foundation NoneCentre of Head and Orthopedics, Rigshospitalet NoneLykfeldt's legat None
6 · The paper itself

Abstract

backgroundPlasma IL-6 and YKL-40 are prognostic biomarkers for OS in patients with different types of solid tumors, but they have not been studied in patients before surgery of metastatic bone disease (MBD) of the extremities. The aim was to evaluate the prognostic value of plasma IL-6 and YKL-40 in patients undergoing surgery for MBD of the extremities. PATIENTS AND

methodsA prospective study included all patients undergoing surgery for MBD in the extremities at a tertiary referral center during the period 2014-2018. Preoperative blood samples from index surgery were included. IL-6 and YKL-40 concentrations in plasma were determined by commercial ELISA. A total of 232 patients (median age 66 years, IQR 58-74; female 51%) were included.

resultsCox regression analysis was performed to identify independent prognostic factors for OS. IL-6 correlated with YKL-40 (rho = 0.46,

conclusionHigh preoperative plasma IL-6 is an independent biomarker of short OS in patients undergoing surgery for MBD.

Indexed as

bone metastasesIL-6inflammatory responseprognostic biomarkersYKL-40

Identifiers

PMID34200156
PMCPMC8201042
OpenAlexW3166691780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.